Letrozole
Letrozole (Femara): what this aromatase inhibitor is, its FDA approval for breast cancer, label warnings, evidence and WADA status.
FDA-approved, prescription only · Evidence grade A · Reviewed
- FDA-approvedBreast cancerPostmenopausal women
Letrozole (Femara). Aromatase inhibitor.
AFDA-approved, prescription only. Evidence grade A: approved, large human trials.
What is Letrozole?
Letrozole is an oral, nonsteroidal aromatase inhibitor. It lowers estrogen by blocking the enzyme that makes it.
Is Letrozole FDA-approved?
FDA first approved Femara (Novartis, NDA 020726) in 1997. It is approved for adjuvant and extended adjuvant treatment of early breast cancer and for advanced breast cancer, all in postmenopausal women. Generics are sold, and it is prescription only. Use in men or to manage steroid side effects is not an approved use.
What does the evidence show for Letrozole?
Large randomized trials in postmenopausal women with breast cancer, including BIG 1-98 and MA-17, support the approved uses.
What are the known risks of Letrozole?
The label has no boxed warning. It warns of bone loss and fractures, higher cholesterol, fatigue, dizziness and sleepiness, and harm to an unborn baby; pregnancy is a contraindication. WADA prohibits aromatase inhibitors at all times in class S4, hormone and metabolic modulators.
How is Letrozole measured?
A tablet, so there is nothing to draw or calculate.
Sources: DailyMed: Femara (letrozole) label; FDA: Femara prescribing information (2024); WADA: The Prohibited List. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.
Keep reading
Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.